Single patient study tests ATGAM safety for rare blood disorder
NCT ID NCT06039020
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 29 times
Summary
This study is checking how safe ATGAM is for people with moderate to severe aplastic anemia, a condition where the bone marrow doesn't make enough blood cells. Only one person is taking part, and they will be watched for 24 weeks to see if any side effects happen. The goal is to confirm safety under real-world use in Japan.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.